Oncocyte Corp Stock Net Income
| OCX Stock | USD 2.71 0.04 1.50% |
OncoCyte Corp fundamentals help investors to digest information that contributes to OncoCyte Corp's financial success or failures. It also enables traders to predict the movement of OncoCyte Stock. The fundamental analysis module provides a way to measure OncoCyte Corp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OncoCyte Corp stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -27.8 M | -29.2 M | |
| Net Loss | -20.9 M | -21.9 M | |
| Net Loss | -66.1 M | -62.8 M | |
| Net Loss | (3.63) | (3.81) | |
| Net Income Per E B T | 1.12 | 1.26 |
OncoCyte | Net Income |
OncoCyte Corp Company Net Income Analysis
OncoCyte Corp's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current OncoCyte Corp Net Income | (27.78 M) |
Most of OncoCyte Corp's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OncoCyte Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
OncoCyte Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for OncoCyte Corp is extremely important. It helps to project a fair market value of OncoCyte Stock properly, considering its historical fundamentals such as Net Income. Since OncoCyte Corp's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of OncoCyte Corp's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of OncoCyte Corp's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
OncoCyte Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, OncoCyte Corp reported net income of (27.78 Million). This is 108.14% lower than that of the Biotechnology sector and 139.66% lower than that of the Health Care industry. The net income for all United States stocks is 104.87% higher than that of the company.
OncoCyte Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OncoCyte Corp's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OncoCyte Corp could also be used in its relative valuation, which is a method of valuing OncoCyte Corp by comparing valuation metrics of similar companies.OncoCyte Corp is currently under evaluation in net income category among its peers.
OncoCyte Corp ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, OncoCyte Corp's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to OncoCyte Corp's managers, analysts, and investors.Environmental | Governance | Social |
OncoCyte Corp Institutional Holders
Institutional Holdings refers to the ownership stake in OncoCyte Corp that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of OncoCyte Corp's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing OncoCyte Corp's value.| Shares | Advisor Group Holdings, Inc. | 2024-06-30 | 1.1 K | Ubs Group Ag | 2024-06-30 | 835 | Bank Of America Corp | 2024-06-30 | 416 | Jpmorgan Chase & Co | 2024-06-30 | 154 | Piscataqua Savings Bank | 2024-09-30 | 25.0 | Coppell Advisory Solutions Llc | 2024-06-30 | 10.0 | Albion Financial Group (utah) | 2024-06-30 | 7.0 | Td Waterhouse Canada Inc | 2024-06-30 | 1.0 | Qube Research & Technologies | 2024-06-30 | 1.0 | Broadwood Capital Inc | 2024-09-30 | 4.9 M | Pura Vida Investments, Llc | 2024-09-30 | 495.3 K |
OncoCyte Fundamentals
| Return On Equity | -1.65 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (55.43) % | ||||
| Current Valuation | 46.25 M | ||||
| Shares Outstanding | 16.84 M | ||||
| Shares Owned By Insiders | 15.95 % | ||||
| Shares Owned By Institutions | 50.58 % | ||||
| Number Of Shares Shorted | 194.19 K | ||||
| Price To Earning | (12.20) X | ||||
| Price To Book | 4.70 X | ||||
| Price To Sales | 64.35 X | ||||
| Revenue | 1.5 M | ||||
| Gross Profit | 188 K | ||||
| EBITDA | (23.12 M) | ||||
| Net Income | (27.78 M) | ||||
| Cash And Equivalents | 45.41 M | ||||
| Cash Per Share | 0.38 X | ||||
| Total Debt | 2.87 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 3.49 X | ||||
| Book Value Per Share | 0.71 X | ||||
| Cash Flow From Operations | (23.32 M) | ||||
| Short Ratio | 6.91 X | ||||
| Earnings Per Share | (4.44) X | ||||
| Target Price | 4.25 | ||||
| Number Of Employees | 43 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 45.62 M | ||||
| Total Asset | 74.89 M | ||||
| Retained Earnings | (289.88 M) | ||||
| Working Capital | 3.5 M | ||||
| Current Asset | 15.28 M | ||||
| Current Liabilities | 3.97 M | ||||
| Net Asset | 74.89 M |
About OncoCyte Corp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OncoCyte Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OncoCyte Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OncoCyte Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.